KR101005630B1 - 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는재조합 수두 바이러스 - Google Patents
수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는재조합 수두 바이러스 Download PDFInfo
- Publication number
- KR101005630B1 KR101005630B1 KR1020047018293A KR20047018293A KR101005630B1 KR 101005630 B1 KR101005630 B1 KR 101005630B1 KR 1020047018293 A KR1020047018293 A KR 1020047018293A KR 20047018293 A KR20047018293 A KR 20047018293A KR 101005630 B1 KR101005630 B1 KR 101005630B1
- Authority
- KR
- South Korea
- Prior art keywords
- virus
- recombinant
- gene
- varicella virus
- homologous
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (31)
- 50-100 %의 상동성을 갖는 2개 이상의 상동 외래 유전자를 포함하며, 상기 유전자 각각이, 수두바이러스 게놈의 비필수 영역인, 상이한 삽입 부위내로 삽입된 재조합 수두바이러스.
- 60-100 %의 상동성을 갖는 2개 이상의 상동 외래 유전자를 포함하는 재조합 수두바이러스.
- 제 1항 또는 제 2항에 있어서, 상기 유전자가 65-75 %의 상동성을 갖는 재조합 수두바이러스.
- 제 1항 또는 제 2항에 있어서, 상기 유전자가 플라비바이러스(flavivirus)로부터 유래된 재조합 수두바이러스.
- 제 4항에 있어서, 상기 플라비바이러스가 뎅기 바이러스인 재조합 수두바이러스.
- 제 4항에 있어서, 상기 유전자가 바이러스의 2개 이상의 상이한 혈청형으로부터 유래된 2개 이상의 상동 유전자인 재조합 수두바이러스.
- 제 4항에 있어서, 상기 유전자가 2개 이상의 PrM 유전자인 재조합 수두바이러스.
- 제 4항에 있어서, 상기 유전자가 4개의 PrM 유전자인 재조합 수두바이러스.
- 제 1항 또는 제 2항에 있어서, 상기 수두바이러스가 백시니아 바이러스인 재조합 수두바이러스.
- 제 9항에 있어서, 상기 백시니아 바이러스가 변형된 백시니아 안카라(MVA) 바이러스인 재조합 수두바이러스.
- 제 10항에 있어서, 상기 MVA가 European Collection of Animal Cell Culture(ECACC)에 기탁번호 V00083008에 기탁된 MVA-BN인 재조합 수두바이러스.
- 제 1항 또는 제 2항에 있어서, 상기 수두바이러스가 사람을 비롯한 포유류 세포에서 복제 결함이 있거나 또는 복제 능력이 없는 재조합 수두바이러스.
- 제 1항 또는 제 2항에 있어서, 상기 유전자가 바이러스 게놈의 천연 산출 결실부위, 유전자 내 영역 또는 양쪽 모두로 삽입되는 재조합 수두바이러스.
- 제 1항 또는 제 2항에 있어서, 의약 또는 백신으로서 사용되는 재조합 수두바이러스.
- 제 1항 또는 제 2항에 따른 재조합 수두바이러스를 포함하는 백신.
- 제 1항 또는 제 2항에 따른 재조합 수두바이러스 및 약제학적으로 허용가능한 담체, 희석제, 보조제, 첨가제 또는 이들의 조합물을 포함하는 약제학적 조성물.
- 사람을 비롯한 동물 생체의 면역반응에 영향을 미치기 위한 제 1항 또는 제 2항에 따른 재조합 수두바이러스.
- 제 15항에 있어서, 사람을 비롯한 동물 생체의 면역반응에 영향을 미치기 위한 백신.
- 제 16항에 있어서, 사람을 포함하는 동물 생체의 면역 반응에 영향을 미치기 위한 약제 조성물.
- 치료 유효량의 제 1항 또는 제 2항에 따른 재조합 수두바이러스를 치료할 동물의 생체에 투여하는 것을 포함하는, 사람을 제외한 동물에서 면역반응에 영향을 미치기 위한 방법.
- - 수두바이러스로 세포를 감염시키는 단계;- 수두바이러스 게놈에 이종인 유전자 및 수두바이러스 게놈의 삽입 부위내로 이종 유전자를 통합시킬 수 있는 수두바이러스 게놈 서열을 포함하는 제 1 벡터 작제물로, 상기 감염된 세포를 형질감염시키는 단계;- 생성된 재조합 수두바이러스를 확인 및 분리하는 단계;- 세포를 감염시키기 위한 이전의 단계로부터 얻은 재조합 수두바이러스 및 수두바이러스 게놈에 이종이며 제 1 벡터 작제물의 유전자에 상동인 다른 유전자를 포함하는 추가 벡터 작제물을 사용함으로써 상기 단계를 반복하는 단계를 포함하는, 제 1항 또는 제 2항에 따른 재조합 수두바이러스의 제조 방법.
- - 수두바이러스 발현 조절 요소의 전사 조절하에 있는 유전자를 포함하는 2개 이상의 벡터 작제물로서, 여기서 상기 각각의 벡터 작제물내에 포함된 유전자가 50-100%의 상동성을 갖는 상동 유전자이며, 상기 유전자 각각이 한쪽 또는 양쪽 말단에서 해당 유전자를 수두바이러스 게놈내로 통합시킬 수 있는 수두바이러스 DNA 서열과 측면을 접하고 있는 것을 특징으로 하는, 2개 이상의 벡터 작제물 및- 재조합 수두바이러스의 게놈내로 통합된 상기 상동 유전자를 지니는 재조합 수두바이러스를 확인, 선택 또는 확인 및 선택하기 위한 핵산(nucleic acids)을 포함하는, 키트.
- 제 22항에 있어서, 상기 각각의 상동 유전자는 한쪽 또는 양쪽 말단에서 각각의 벡터 작제물의 상동 유전자를 수두바이러스 게놈의 상이한 삽입 부위내로 통합시킬 수 있는 수두바이러스 DNA 서열과 측면을 접하고 있는 것을 특징으로 하는, 키트.
- 제 1항 또는 제 2항에 따른 재조합 수두바이러스의 재조합 수두바이러스 게놈으로부터 유래되거나 재조합 수두바이러스 게놈에 상동이며, 2개 이상의 상동 유전자 및 수두바이러스 게놈 서열의 일부 또는 전부를 포함하는, 핵산(nucleic acids).
- 제 1항 또는 제 2항에 따른 재조합 수두바이러스에 의해 감염된 세포를 검출하는 방법으로서, 제 24항에 따른 핵산(nucleic acids)을 상기 세포에 투여하는 것을 포함하는 방법.
- 제 1항 또는 제 2항에 따른 재조합 수두바이러스를 확인하는 방법으로서, 제 24항에 따른 핵산(nucleic acids)을 상기 바이러스에 투여하는 것을 포함하는 방법.
- 상동 외래 유전자, 상동 외래 유전자의 삽입부위와 관련된 측면 서열, 또는 상기 상동 외래 유전자와 상기 측면 서열 둘 모두를 선택적으로 증폭시키는 프라이머와 세포를 접촉시키는 단계를 포함하는, 제 1항 또는 제 2항에 따른 재조합 수두바이러스로 감염된 세포의 검출 방법.
- 상동 외래 유전자, 상동 외래 유전자의 삽입부위와 관련된 측면 서열, 또는 상기 상동 외래 유전자와 상기 측면 서열 둘 모두를 선택적으로 증폭시키는 프라이머와 세포를 접촉시키는 단계를 포함하는, 제 1항 또는 제 2항에 따른 재조합 수두바이러스로 감염된 세포의 확인 방법.
- 치료 유효량의 제 15항에 따른 백신을 치료할 동물에게 투여하는 것을 포함하는, 사람을 제외한 동물 생체에서 면역반응에 영향을 미치기 위한 방법.
- 치료 유효량의 제 16항에 따른 약제 조성물을 치료할 동물에게 투여하는 것을 포함하는, 사람을 제외한 동물의 생체에서 면역반응에 영향을 미치기 위한 방법.
- 제 1항 또는 제 2항에 따른 재조합 수두바이러스를 포함하는 세포.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200200752 | 2002-05-16 | ||
DKPA200200753 | 2002-05-16 | ||
DKPA200200752 | 2002-05-16 | ||
DKPA200200753 | 2002-05-16 | ||
PCT/EP2003/005047 WO2003097846A1 (en) | 2002-05-16 | 2003-05-14 | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107021891A Division KR101138067B1 (ko) | 2002-05-16 | 2003-05-14 | 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는 재조합 수두 바이러스 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040108809A KR20040108809A (ko) | 2004-12-24 |
KR101005630B1 true KR101005630B1 (ko) | 2011-01-05 |
Family
ID=29551228
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047018293A KR101005630B1 (ko) | 2002-05-16 | 2003-05-14 | 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는재조합 수두 바이러스 |
KR1020047018165A KR101041691B1 (ko) | 2002-05-16 | 2003-05-14 | 변형 백시니아 바이러스 안카라(mva)의 게놈내삽입부위로서의 유전자내 영역 |
KR1020117031095A KR20120002627A (ko) | 2002-05-16 | 2003-05-14 | 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는 재조합 수두 바이러스 |
KR1020107021891A KR101138067B1 (ko) | 2002-05-16 | 2003-05-14 | 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는 재조합 수두 바이러스 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047018165A KR101041691B1 (ko) | 2002-05-16 | 2003-05-14 | 변형 백시니아 바이러스 안카라(mva)의 게놈내삽입부위로서의 유전자내 영역 |
KR1020117031095A KR20120002627A (ko) | 2002-05-16 | 2003-05-14 | 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는 재조합 수두 바이러스 |
KR1020107021891A KR101138067B1 (ko) | 2002-05-16 | 2003-05-14 | 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는 재조합 수두 바이러스 |
Country Status (23)
Country | Link |
---|---|
US (14) | US7550147B2 (ko) |
EP (3) | EP1407033B1 (ko) |
JP (4) | JP4895505B2 (ko) |
KR (4) | KR101005630B1 (ko) |
CN (6) | CN102199628A (ko) |
AT (1) | ATE315660T1 (ko) |
AU (4) | AU2003236646B2 (ko) |
BR (2) | BRPI0311178B8 (ko) |
CA (3) | CA2812019A1 (ko) |
DE (1) | DE60303218T2 (ko) |
DK (2) | DK1506301T3 (ko) |
EA (3) | EA020230B1 (ko) |
ES (1) | ES2256776T3 (ko) |
HK (2) | HK1076642A1 (ko) |
IL (4) | IL164172A0 (ko) |
MX (2) | MXPA04011194A (ko) |
NO (3) | NO334273B1 (ko) |
NZ (2) | NZ536502A (ko) |
PL (2) | PL216760B1 (ko) |
PT (1) | PT1407033E (ko) |
SI (1) | SI1407033T1 (ko) |
UA (1) | UA82479C2 (ko) |
WO (2) | WO2003097846A1 (ko) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4101327C1 (ko) * | 1991-01-18 | 1991-10-24 | Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De | |
CN101676389A (zh) | 2000-11-23 | 2010-03-24 | 巴法里安诺迪克有限公司 | 改良安卡拉痘苗病毒变体 |
DE60314823T3 (de) * | 2002-04-19 | 2017-11-16 | Bavarian Nordic A/S | Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene |
AU2003236646B2 (en) | 2002-05-16 | 2009-01-15 | Bavarian Nordic A/S | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
DK1434858T4 (en) * | 2002-09-05 | 2019-04-01 | Bavarian Nordic As | PROCEDURE FOR AMPLIFICATION OF A POXVIRUS UNDER SERUM-FREE CONDITIONS |
US7638134B2 (en) | 2003-02-20 | 2009-12-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Insertion sites in fowlpox vectors |
GB2402391A (en) * | 2003-06-04 | 2004-12-08 | Oxxon Pharmaccines Ltd | Fowlpox recombinant genome |
EP1807508A4 (en) * | 2004-11-05 | 2008-03-12 | Us Gov Health & Human Serv | METHODS FOR PREPARING CELLS AND VIRUSES |
EP1855720B2 (en) * | 2005-02-23 | 2023-04-26 | Bavarian Nordic A/S | Use of a modified proxvirus for the rapid induction of immunity against a poxvirus or other infectious agents |
JP5424871B2 (ja) * | 2006-05-19 | 2014-02-26 | グライコフィ, インコーポレイテッド | 組換えベクター |
DK2402451T3 (en) * | 2006-08-25 | 2018-06-25 | The Government Of The Us Secretary Department Of Health And Human Services | Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector |
US20090098529A1 (en) * | 2006-10-16 | 2009-04-16 | Nanhai Chen | Methods for attenuating virus strains for diagnostic and therapeutic uses |
EP2462930B1 (en) * | 2006-11-09 | 2017-05-31 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using prime-boost approach |
US8440202B2 (en) * | 2006-11-09 | 2013-05-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
PE20081723A1 (es) * | 2007-01-30 | 2008-12-14 | Transgene Sa | Vacuna contra el papilomavirus |
US8268327B2 (en) | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
BRPI0810305A2 (pt) * | 2007-05-15 | 2018-07-10 | Transgene Sa | "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição" |
TW200907058A (en) * | 2007-05-30 | 2009-02-16 | Wyeth Corp | Raccoon poxvirus expressing rabies glycoproteins |
CA2681183A1 (en) * | 2007-05-30 | 2008-12-11 | Wyeth | Raccoon poxvirus expressing genes of feline antigens |
DK2207564T3 (en) | 2007-10-18 | 2017-01-16 | Bavarian Nordic As | USE OF VAT FOR TREATMENT OF PROSTATACANCES |
EP2303322A1 (en) * | 2008-06-20 | 2011-04-06 | Bavarian Nordic A/S | Recombinant modified vaccinia virus measles vaccine |
KR100894430B1 (ko) * | 2008-11-11 | 2009-04-22 | 시스템디엔디(주) | 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법 |
MX2011005171A (es) * | 2008-11-21 | 2011-05-30 | Bavarian Nordic As | Vector que comprende multiples secuencias de nucleotidos homologas. |
AU2010305030A1 (en) | 2009-10-08 | 2012-05-10 | Bavarian Nordic A/S | Generation of a broad T-cell response in humans against HIV |
WO2011047324A1 (en) | 2009-10-16 | 2011-04-21 | The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
WO2011087839A1 (en) | 2009-12-22 | 2011-07-21 | Baxter International Inc. | Vaccine to influenza a virus |
EP2552490A4 (en) * | 2010-03-26 | 2013-12-18 | Emergent Product Dev Gaithersburg Inc | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF |
US10087423B2 (en) | 2010-07-20 | 2018-10-02 | Bavarian Nordic A/S | Method for harvesting expression products |
CA2811739A1 (en) * | 2010-09-23 | 2012-03-29 | Baxter International Inc. | Recombinant viral vectors and methods for inducing an immune response to yellow fever virus |
EP2627774B1 (en) | 2010-10-15 | 2018-11-21 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) influenza vaccine |
CN114262690A (zh) | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
DK2788021T3 (en) | 2011-12-09 | 2017-04-10 | Bavarian Nordic As | POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C |
EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
KR20150021088A (ko) | 2012-06-05 | 2015-02-27 | 디 오스트레일리언 내셔널 유니버시티 | 인터루킨-4 길항제를 이용한 백신접종 |
JP6523955B2 (ja) | 2012-08-01 | 2019-06-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組換え改変ワクシニアウイルスアンカラ(mva)rsウイルス(rsv)ワクチン |
WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
CA2888367A1 (en) | 2012-10-19 | 2014-04-24 | Bavarian Nordic, Inc. | Methods and compositions for the treatment of cancer |
WO2014139587A1 (en) * | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
KR102212253B1 (ko) * | 2013-03-15 | 2021-02-04 | 세멘티스 리미티드 | 면역 조절 |
WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
KR101645642B1 (ko) | 2014-10-16 | 2016-08-11 | 대한민국 | Kvac103 유래의 재조합 백시니아 바이러스 |
KR101623498B1 (ko) | 2014-10-16 | 2016-05-24 | 대한민국 | 약독화 백시니아 바이러스주 kvac103 |
CN107735103B (zh) | 2015-02-25 | 2022-05-27 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的非复制型的修饰的痘苗病毒安卡拉(mva)作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合 |
CN116173193A (zh) | 2015-04-17 | 2023-05-30 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
KR20160140075A (ko) * | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
CA2987159A1 (en) * | 2015-06-15 | 2016-12-22 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine |
FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
CN106591361A (zh) * | 2015-10-20 | 2017-04-26 | 钱文斌 | 一种重组痘溶瘤病毒及其构建方法和应用 |
US11278607B2 (en) | 2016-01-08 | 2022-03-22 | Geovax, Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
WO2017129765A1 (en) | 2016-01-29 | 2017-08-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
WO2017136419A1 (en) * | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
JP7034080B2 (ja) | 2016-02-25 | 2022-03-11 | メモリアル スローン ケタリング キャンサー センター | ヒトflt3lを発現する組換えmvaまたはmvaδe3lおよび固形腫瘍に対する免疫療法薬としてのそれらの使用 |
WO2017147553A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
WO2017192418A1 (en) | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
KR20190050787A (ko) * | 2016-08-19 | 2019-05-13 | 세멘티스 리미티드 | 바이러스 백신 |
EP3518656A4 (en) * | 2016-09-30 | 2020-09-30 | Monsanto Technology LLC | METHOD OF SELECTING TARGETS FOR SITE-SPECIFIC GENOME MODIFICATION IN PLANTS |
WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
CN110958887B (zh) * | 2017-06-15 | 2023-10-31 | 扬森疫苗与预防公司 | 编码hiv抗原的痘病毒载体及其使用方法 |
US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
EP3790578A4 (en) | 2018-05-11 | 2022-04-06 | City of Hope | GENETICALLY MODIFIED RECOMBINANT VACCINIA-ANKARA (RMVA) VACCINE WITH IMPROVED STABILITY AND METHODS FOR THEIR PRODUCTION |
CN112512569A (zh) * | 2018-05-11 | 2021-03-16 | 希望之城 | 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途 |
CN111979204B (zh) * | 2019-05-24 | 2023-10-13 | 杭州功楚生物科技有限公司 | 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途 |
EP4058058A1 (en) | 2019-11-14 | 2022-09-21 | Aelix Therapeutics S.L. | Dosage regimens for vaccines |
TW202203966A (zh) * | 2020-03-31 | 2022-02-01 | 澳大利亞商賽門蒂斯公司 | 用於防範covid-19之以減毒的痘病毒載體為底質之疫苗 |
WO2024011250A1 (en) | 2022-07-08 | 2024-01-11 | Viromissile, Inc. | Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
JPH0795956B2 (ja) * | 1986-09-22 | 1995-10-18 | 京都大学長 | ポックスウイルス由来発現制御領域 |
US5093258A (en) * | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
US5651972A (en) | 1989-04-21 | 1997-07-29 | University Of Florida Research Foundation, Inc. | Use of recombinant swine poxvirus as a live vaccine vector |
MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
US6893845B1 (en) * | 1990-09-28 | 2005-05-17 | Applied Molecular Evolution, Inc. | Surface expression libraries of heteromeric receptors |
KR100242671B1 (ko) * | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
BE1004877A3 (fr) * | 1991-05-27 | 1993-02-16 | Solvay | Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus. |
FR2679249B1 (fr) * | 1991-07-15 | 1993-11-26 | Centre Nal Recherc Scientifique | Souches de levure avec integration stable de genes heterologues. |
JPH06509235A (ja) | 1991-07-26 | 1994-10-20 | ヴァイロジェネティクス コーポレイション | 伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン |
EP0561034B1 (en) * | 1991-08-26 | 1999-06-09 | IMMUNO Aktiengesellschaft | Direct molecular cloning of a modified chordopox virus genome |
DK0538496T3 (da) | 1991-08-26 | 2004-02-23 | Baxter Healthcare Sa | Rekombinant fjerkrækoppevirus med intakt FPV tk-gen |
US5676950A (en) | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
EP0753581A1 (en) * | 1995-07-10 | 1997-01-15 | Immuno Ag | Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines |
DE19629828A1 (de) * | 1996-07-24 | 1998-01-29 | Bayer Ag | Carbanilide |
EP0951555A2 (en) * | 1996-09-24 | 1999-10-27 | Bavarian Nordic Research Institute A/S | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines |
AUPP380598A0 (en) * | 1998-05-29 | 1998-06-25 | Commonwealth Scientific And Industrial Research Organisation | Genetically manipulated entomopoxvirus |
US6252871B1 (en) | 1998-07-01 | 2001-06-26 | Powerwave Technologies, Inc. | Switchable combiner/splitter |
US20040265324A1 (en) * | 1999-03-23 | 2004-12-30 | Cardosa Mary Jane | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
US6682742B1 (en) * | 1999-05-28 | 2004-01-27 | Gsf Forschungszentrum Fur Unwelt Und Gesundheit Gmbh | Vector for integration of heterologous sequences into poxviral genomes |
SI1263936T1 (sl) * | 2000-03-14 | 2006-06-30 | Bavarian Nordic As | Spremenjen sev modificiranega virusa vakcinacije Ankara (MVA) |
CA2341356C (en) * | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
IL154169A0 (en) * | 2000-08-29 | 2003-07-31 | Wyeth Corp | Packaging of positive-strand rna virus replicon particles |
CN101676389A (zh) | 2000-11-23 | 2010-03-24 | 巴法里安诺迪克有限公司 | 改良安卡拉痘苗病毒变体 |
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
AU2003236646B2 (en) | 2002-05-16 | 2009-01-15 | Bavarian Nordic A/S | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
CN1717488A (zh) * | 2002-11-25 | 2006-01-04 | 巴法里安诺迪克有限公司 | 包含至少两个牛痘ati启动子的重组痘病毒 |
-
2003
- 2003-05-14 AU AU2003236646A patent/AU2003236646B2/en not_active Expired
- 2003-05-14 KR KR1020047018293A patent/KR101005630B1/ko active IP Right Grant
- 2003-05-14 MX MXPA04011194A patent/MXPA04011194A/es active IP Right Grant
- 2003-05-14 IL IL16417203A patent/IL164172A0/xx unknown
- 2003-05-14 CA CA 2812019 patent/CA2812019A1/en not_active Abandoned
- 2003-05-14 CN CN2011100588236A patent/CN102199628A/zh active Pending
- 2003-05-14 CN CN200910208520A patent/CN101831411A/zh active Pending
- 2003-05-14 US US10/514,761 patent/US7550147B2/en not_active Expired - Lifetime
- 2003-05-14 CN CN038111063A patent/CN1653183B/zh not_active Expired - Lifetime
- 2003-05-14 DE DE2003603218 patent/DE60303218T2/de not_active Expired - Lifetime
- 2003-05-14 EP EP20030752741 patent/EP1407033B1/en not_active Expired - Lifetime
- 2003-05-14 SI SI200330215T patent/SI1407033T1/sl unknown
- 2003-05-14 EA EA200900180A patent/EA020230B1/ru not_active IP Right Cessation
- 2003-05-14 AT AT03752741T patent/ATE315660T1/de active
- 2003-05-14 WO PCT/EP2003/005047 patent/WO2003097846A1/en active Application Filing
- 2003-05-14 KR KR1020047018165A patent/KR101041691B1/ko active IP Right Grant
- 2003-05-14 DK DK03735384T patent/DK1506301T3/da active
- 2003-05-14 EP EP10008120.7A patent/EP2253709B1/en not_active Expired - Lifetime
- 2003-05-14 UA UA20041109409A patent/UA82479C2/uk unknown
- 2003-05-14 MX MXPA04010713A patent/MXPA04010713A/es active IP Right Grant
- 2003-05-14 EA EA200401507A patent/EA007811B1/ru not_active IP Right Cessation
- 2003-05-14 NZ NZ536502A patent/NZ536502A/en not_active IP Right Cessation
- 2003-05-14 JP JP2004506500A patent/JP4895505B2/ja not_active Expired - Lifetime
- 2003-05-14 ES ES03752741T patent/ES2256776T3/es not_active Expired - Lifetime
- 2003-05-14 WO PCT/EP2003/005045 patent/WO2003097845A1/en active IP Right Grant
- 2003-05-14 NZ NZ536501A patent/NZ536501A/en not_active IP Right Cessation
- 2003-05-14 BR BRPI0311178A patent/BRPI0311178B8/pt not_active IP Right Cessation
- 2003-05-14 CN CN2012101928085A patent/CN102703393A/zh active Pending
- 2003-05-14 CA CA2481799A patent/CA2481799C/en not_active Expired - Lifetime
- 2003-05-14 EA EA200401506A patent/EA012160B1/ru not_active IP Right Cessation
- 2003-05-14 CA CA2481521A patent/CA2481521C/en not_active Expired - Lifetime
- 2003-05-14 AU AU2003242540A patent/AU2003242540A1/en not_active Abandoned
- 2003-05-14 CN CN2012101926963A patent/CN102719408A/zh active Pending
- 2003-05-14 DK DK03752741T patent/DK1407033T3/da active
- 2003-05-14 EP EP20030735384 patent/EP1506301B1/en not_active Expired - Lifetime
- 2003-05-14 US US10/510,189 patent/US7338662B2/en not_active Expired - Lifetime
- 2003-05-14 KR KR1020117031095A patent/KR20120002627A/ko not_active Application Discontinuation
- 2003-05-14 JP JP2004506501A patent/JP4693092B2/ja not_active Expired - Lifetime
- 2003-05-14 IL IL16417703A patent/IL164177A0/xx active IP Right Grant
- 2003-05-14 PL PL372093A patent/PL216760B1/pl unknown
- 2003-05-14 PT PT03752741T patent/PT1407033E/pt unknown
- 2003-05-14 PL PL372088A patent/PL218318B1/pl unknown
- 2003-05-14 KR KR1020107021891A patent/KR101138067B1/ko active IP Right Grant
- 2003-05-14 CN CNB038111225A patent/CN100494388C/zh not_active Expired - Lifetime
- 2003-05-14 BR BR0310051A patent/BR0310051A/pt not_active IP Right Cessation
-
2004
- 2004-11-12 NO NO20044940A patent/NO334273B1/no not_active IP Right Cessation
- 2004-12-16 NO NO20045480A patent/NO336489B1/no not_active IP Right Cessation
-
2005
- 2005-09-29 HK HK05108644A patent/HK1076642A1/xx not_active IP Right Cessation
- 2005-09-30 HK HK05108710A patent/HK1076836A1/xx not_active IP Right Cessation
-
2007
- 2007-11-15 US US11/985,510 patent/US9109233B2/en active Active
-
2008
- 2008-07-28 IL IL19308808A patent/IL193088A/en active IP Right Grant
- 2008-07-28 IL IL193087A patent/IL193087A/en active IP Right Grant
- 2008-12-09 AU AU2008255213A patent/AU2008255213B2/en not_active Expired
- 2008-12-19 US US12/339,743 patent/US20100173388A1/en not_active Abandoned
-
2009
- 2009-02-03 AU AU2009200380A patent/AU2009200380C1/en not_active Expired
- 2009-05-19 US US12/468,120 patent/US7964374B2/en not_active Expired - Lifetime
- 2009-05-19 US US12/468,127 patent/US8034354B2/en not_active Expired - Lifetime
-
2010
- 2010-08-05 JP JP2010176511A patent/JP2011004755A/ja active Pending
- 2010-08-05 JP JP2010176512A patent/JP5777199B2/ja not_active Expired - Lifetime
- 2010-09-30 US US12/894,589 patent/US20110053260A1/en not_active Abandoned
- 2010-09-30 US US12/894,550 patent/US20110053259A1/en not_active Abandoned
-
2011
- 2011-04-15 US US13/087,715 patent/US8288125B2/en not_active Expired - Lifetime
- 2011-04-15 US US13/087,649 patent/US8309326B2/en not_active Expired - Lifetime
- 2011-09-15 US US13/233,329 patent/US8414900B2/en not_active Expired - Lifetime
- 2011-09-16 US US13/234,230 patent/US8435543B2/en not_active Expired - Lifetime
- 2011-09-29 NO NO20111324A patent/NO20111324A1/no not_active Application Discontinuation
-
2012
- 2012-02-13 US US13/371,580 patent/US20120178157A1/en not_active Abandoned
-
2013
- 2013-05-02 US US13/886,093 patent/US8741308B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101005630B1 (ko) | 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는재조합 수두 바이러스 | |
EP1567653B1 (en) | Recombinant poxvirus comprising at least two cowpox ati promoters | |
JP2005534326A (ja) | アビポックスウイルスの力価を増加させるためのワクシニアウイルス宿主域遺伝子 | |
JP2005525821A (ja) | 牛痘atiプロモーターを用いた変異ワクシニアウイルスアンカラ中の遺伝子の発現 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131127 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141125 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151203 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161124 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171129 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191126 Year of fee payment: 10 |